The primary efficacy endpoint was transform from baseline MADRS score. This shorter-expression study identified that, compared to intranasal placebo in addition oral antidepressant, intranasal esketamine in conjunction with an oral antidepressant drastically improved depressive indicators after 4 weeks by a mean difference of four points to the MAD